3590
Validation of the “budget impact analysis” model of the introduction of dolutegravir drug into the public procurement of antiretroviral drugs in the Russian Federation
The article demonstrates validation results of the “budget impact” model of introduction of the drug dolutegravir into the public procurement of antiretroviral drugs on the territory of the Russian Federation provided by ViiV Healthcare.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kulikov A.Yu., Babiy V.V. Validation of the “budget impact analysis” model of the introduction of dolutegravir drug into the public procurement of antiretroviral drugs in the Russian Federation // Pharmacoeconomics: theory and practice. - 2017. - Vol.5, №3. - P.68-70 DOI: https://doi.org/10.30809/phe.3.2017.2
Comments0